Playing the ACE Card in LBAs
The precision of affinity capillary electrophoresis makes it a strong option for advancing drug development.
Hermann Wätzig |
Ligand binding assays (LBAs) are indispensable for biological understanding – and to develop new pharmaceuticals. Due to their tremendous importance, LBAs need to be biologically relevant, precise and accurate. Unfortunately, sometimes they are not. In fact, the data obtained often vary so strongly that only variations by orders of magnitude are considered as real changes. This questionable data quality still limits progress in drug discovery.
Read the full article now
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Analytical Scientist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.
- S. El Deeb et al., “Recent advances in capillary electrophoretic migration techniques for pharmaceutical analysis”, Electrophoresis, 37, 1591-1608 (2016).
- H. A. Alhazmi et al., “A comprehensive platform to investigate protein–metal ion interactions by affinity capillary electrophoresis”, Journal of Pharmaceutical and Biomedical Analysis 107, 311–317 (2015).